Polpharma Biologics na CEBioForum 2024
CEBioForum 2024 is an annual international conference for the biotechnology sector and also the largest industry even…
Konstantin Matentzoglu for Puls Biznesu
We are expanding our research portfolio – that’s what you’ll read about in Puls Biznesu. Editor Marcel Zatoński spoke…
Polpharma Biologics’ investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio®*
Polpharma Biologics, an international biotech company dedicated to the development and manufacturing of biosimilars,…
Polpharma Biologics announces approval of Europe’s first and only biosimilar for multiple sclerosis – Tyruko® (natalizumab)
Polpharma Biologics, an international biotech company dedicated to the development and manufacturing of biosimilars,…
Polpharma Biologics announces FDA approval of Tyruko® – first and only approved biosimilar to Tysabri®* for relapsing forms of multiple sclerosis
Polpharma Biologics announces FDA approval of Tyruko® – first and only approved biosimi…
Polpharma Biologics announces first-of-a-kind multiple sclerosis biosimilar natalizumab receives positive CHMP opinion
Polpharma Biologics, an international biotech company dedicated to the development and manufacture of biosimilars, an…
European Commission approves FYB201/Ranivisio®1 (Ranivisio – Ranibizumab), a biosimilar to Lucentis®2
Amsterdam Munich, Zug – Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (…
U.S. Food and Drug Administration (FDA) approves FYB201/CIMERLI™* (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®**
3rd of August 2022 U.S. Food and Drug Administration (FDA) approves FYB201/CIMERLITM* (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®** Amsterdam, Munich, Zug – Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (“Bioeq”), jointly announce that the U.S. Food and Drug Administration (“FDA”) has approved CIMERLI™ (ranibizumab-eqrn), a biosimilar product […]
Polpharma Biologics announces FDA file acceptance for review of natalizumab, first proposed biosimilar to Tysabri®
Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) has accepted the first-ever Biol…
Polpharma Biologics announces EMA acceptance of Marketing Authorization Application for proposed biosimilar natalizumab
Warszawa, 18 lipca 2022 r. Polpharma Biologics, polska firma biotechnologiczna zajmująca się rozwojem i produkcją leków biologicznych ogłosiła, że Europejska Agencja Leków (European Medicines Agency – EMA) przyjęła wniosek (Marketing Authorization Application – MAA) o wydanie pozwolenia na dopuszczenie do obrotu na terenie Unii Europejskiej – leku biopodobnego zawierającego przeciwciało monoklonalne natalizumab1. Lek jest stosowany […]